PMV Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

PMVP$1.22-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Condensed Consolidated Statements of Opera tions and Comprehensive Loss

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$14,676	$18,400	$30,006	$35,841
General and administrative	4,205	4,479	7,894	8,600
Total operating expenses	18,881	22,879	37,900	44,441
Loss from operations	(18,881)	(22,879)	(37,900)	(44,441)
Other income (expense):
Interest income, net	788	1,690	1,768	3,625
Other income (expense), net	10	(16)	11	(21)
Total other income	798	1,674	1,779	3,604
Loss before (benefit) for income taxes	(18,083)	(21,205)	(36,121)	(40,837)
Provision (benefit) for income taxes	3	5	3	(2,191)
Net loss	(18,086)	(21,210)	(36,124)	(38,646)
Unrealized (loss) on available for sale investments, net of tax	(67)	(61)	(168)	(123)
Foreign currency translation gain (loss)	—	(2)	2	6
Total other comprehensive loss	(67)	(63)	(166)	(117)
Total comprehensive loss	$(18,153)	$(21,273)	$(36,290)	$(38,763)
Net loss per share -- basic and diluted	$(0.34)	$(0.41)	$(0.68)	$(0.74)
Weighted-average common shares outstanding	53,386,909	52,010,827	53,359,490	51,981,607

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.